COPD treatment pathways in France: a retrospective analysis of electronic medical record data from general practitioners

References

• Global Initiative for Chronic Obstructive Lung DiseaseGlobal Strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease Updated 2018 Available from: https://goldcopd.org/wp-content/uploads/2017/11/GOLD-2018-v6.0-FINAL-revised-20-Nov_WMS.pdfAccessed November 21, 2018
   Google Scholar
• GBD 2016 Causes of Death CollaboratorsGlobal, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the Global Burden of Disease Study 2016Lancet2017390101001151121028919116
   PubMed Web of Science ®Google Scholar
• World Health Organization [webpage on the Internet]Chronic respiratory diseases. Burden of COPD Available from: http://www.who.int/respiratory/copd/burden/en/Accessed October 27, 2017
   Google Scholar
• LaurendeauCChouaidCRocheNTerriouxPGourmelenJDetournayBPrise en charge et coûts de la bronchopneumopathie chronique obstructive en France en 2011. [Management and costs of chronic pulmonary obstructive disease in France in 2011]Rev Mal Respir2015327682691 French25613440
   PubMed Web of Science ®Google Scholar
• BatemanEDFergusonGTBarnesNDual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE studyEur Respir J20134261484149423722616
   PubMed Web of Science ®Google Scholar
• BuhlRMaltaisFAbrahamsRTiotropium and olodaterol fixed-dose combination versus mono-components in COPD (GOLD 2–4)Eur Respir J201545496997925573406
   PubMed Web of Science ®Google Scholar
• DecramerMAnzuetoAKerwinEEfficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trialsLancet Respir Med20142647248624835833
   PubMed Web of Science ®Google Scholar
• Maleki-YazdiMRKaelinTRichardNZvarichMChurchAEfficacy and safety of umeclidinium/vilanterol 62.5/25 mcg and tiotropium 18 mcg in chronic obstructive pulmonary disease: results of a 24-week, randomized, controlled trialRespir Med2014108121752176025458157
   PubMed Web of Science ®Google Scholar
• ObaYSarvaSTDiasSEfficacy and safety of long-acting ®-agonist/long-acting muscarinic antagonist combinations in COPD: a network meta-analysisThorax2016711152526490732
   PubMed Web of Science ®Google Scholar
• SinghDFergusonGTBolitschekJTiotropium + olodaterol shows clinically meaningful improvements in quality of lifeRespir Med2015109101312131926320402
   PubMed Web of Science ®Google Scholar
• WedzichaJADecramerMFickerJHAnalysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group studyLancet Respir Med20131319920924429126
   PubMed Web of Science ®Google Scholar
• ZuwallackRAllenLHernandezGTingNAbrahamsREfficacy and safety of combining olodaterol Respimat(®) and tiotropium HandiHaler(®) in patients with COPD: results of two randomized, double-blind, active-controlled studiesInt J Chron Obstruct Pulmon Dis201491133114425342898
   PubMed Web of Science ®Google Scholar
• FabbriLMRoversiSBeghéBTriple therapy for symptomatic patients with COPDLancet2017389100821864186528385354
   PubMed Web of Science ®Google Scholar
• LeeTAWilkeCJooMOutcomes associated with tiotropium use in patients with chronic obstructive pulmonary diseaseArch Intern Med2009169151403141019667304
   PubMed Web of Science ®Google Scholar
• LipsonDABarnacleHBirkRFULFIL Trial: Once-Daily Triple Therapy for Patients with Chronic Obstructive Pulmonary DiseaseAm J Respir Crit Care Med2017196443844628375647
   PubMed Web of Science ®Google Scholar
• LipsonDABarnhartFBrealeyNOnce-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPDN Engl J Med2018378181671168029668352
   PubMed Web of Science ®Google Scholar
• Rojas-ReyesMXGarcia MoralesOMDennisRJKarnerCCombination inhaled steroid and long-acting beta(2)-agonist in addition to tiotropium versus tiotropium or combination alone for chronic obstructive pulmonary diseaseCochrane Database Syst Rev20166CD008532
   Google Scholar
• SinghDBrooksJHaganGCahnAO’ConnorBJSuperiority of “triple” therapy with salmeterol/fluticasone propionate and tiotropium bromide versus individual components in moderate to severe COPDThorax200863759259818245142
   PubMed Web of Science ®Google Scholar
• SinghDPapiACorradiMSingle inhaler triple therapy versus inhaled corticosteroid plus long-acting ®2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trialLancet20163881004896397327598678
   PubMed Web of Science ®Google Scholar
• TabbererMLomasDABirkROnce-daily triple therapy in patients with COPD: patient-reported symptoms and quality of lifeAdv Ther2018351567129313286
   PubMed Web of Science ®Google Scholar
• VestboJPapiACorradiMSingle inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trialLancet2017389100821919192928385353
   PubMed Web of Science ®Google Scholar
• Société de Pneumologie de Langue Francaise (SPLF)Traitement pharmacologique de la BPCO. [Pharmacological treatment of COPD]Rev Mal Respir201021S1S19S35 French
   Google Scholar
• ZysmanMChabotFDevillierPPharmacological treatment optimization for stable chronic obstructive pulmonary disease. Proposals from the Société de Pneumologie de Langue FrançaiseRev Mal Respir2016331091193627890625
   PubMed Web of Science ®Google Scholar
• LandisSHWurstKLeHVBonarKPunekarYSCan assessment of disease burden prior to changes in initial COPD maintenance treatment provide insight into remaining unmet needs? a retrospective database study in UK primary careCOPD2017141808527819513
   PubMedGoogle Scholar
• ISPEGuidelines for good pharmacoepidemiology practices (GPP)Pharmacoepidemiol Drug Saf200817220020817868186
   PubMed Web of Science ®Google Scholar
• von ElmEAltmanDGEggerMThe Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studiesJ Clin Epidemiol200861434434918313558
   PubMed Web of Science ®Google Scholar
• EverittBSCluster Analysis3rd edLondonEdward Arnold Publishers1993
   Google Scholar
• Breekveldt-PostmaNSKoerselmanJErkensJALammersJWHeringsRMEnhanced persistence with tiotropium compared with other respiratory drugs in COPDRespir Med200710171398140517368011
   PubMed Web of Science ®Google Scholar
• CramerJABradley-KennedyCScaleraATreatment persistence and compliance with medications for chronic obstructive pulmonary diseaseCan Respir J2007141252917315055
   PubMed Web of Science ®Google Scholar
• Penning-van BeestFvan Herk-SukelMGaleRLammersJWHeringsRThree-year dispensing patterns with long-acting inhaled drugs in COPD: a database analysisRespir Med2011105225926520705441
   PubMed Web of Science ®Google Scholar
• WurstKEPunekarYSShuklaATreatment evolution after COPD diagnosis in the UK primary care settingPLoS One201499e10529625180802
   PubMed Web of Science ®Google Scholar
• WurstKESt LaurentSMullerovaHDavisKJCharacteristics of patients with COPD newly prescribed a long-acting bronchodilator: a retrospective cohort studyInt J Chron Obstruct Pulmon Dis201491021103125285002
   PubMed Web of Science ®Google Scholar
• BelleudiVdi MartinoMCasciniSThe impact of adherence to inhaled drugs on 5-year survival in COPD patients: a time dependent approachPharmacoepidemiol Drug Saf201625111295130427396695
   PubMed Web of Science ®Google Scholar
• Montes de OcaMMenezesAWehrmeisterFCAdherence to inhaled therapies of COPD patients from seven Latin American countries: The LASSYC studyPLoS One20171211e018677729140978
   PubMed Web of Science ®Google Scholar
• Simoni-WastilaLWeiYJQianJAssociation of chronic obstructive pulmonary disease maintenance medication adherence with all-cause hospitalization and spending in a Medicare populationAm J Geriatr Pharmacother201210320121022521808
   PubMedGoogle Scholar
• JochmannANeubauerFMiedingerDSchafrothSTammMLeuppiJDGeneral practitioner’s adherence to the COPD GOLD guidelines: baseline data of the Swiss COPD Cohort StudySwiss Med Wkly2010140
   PubMed Web of Science ®Google Scholar
• PerezXWisniveskyJPLurslurchachaiLKleinmanLCKronishIMBarriers to adherence to COPD guidelines among primary care providersRespir Med2012106337438122000501
   PubMed Web of Science ®Google Scholar
• PriceDWestDBrusselleGManagement of COPD in the UK primary-care setting: an analysis of real-life prescribing patternsInt J Chron Obstruct Pulmon Dis2014988990425210450
   PubMed Web of Science ®Google Scholar
• SalinasGDWilliamsonJCKalhanRBarriers to adherence to chronic obstructive pulmonary disease guidelines by primary care physiciansInt J Chron Obstruct Pulmon Dis2011617117921468169
   PubMed Web of Science ®Google Scholar
• Gruffydd-JonesKBrusselleGJonesRChanges in initial COPD treatment choice over time and factors influencing prescribing decisions in UK primary care: in UK primary care: a real-world, retrospective, observationalNPJ Prim Care Respir Med2016261600228358398
   PubMed Web of Science ®Google Scholar
• AisanovZBaiCBauerleOPrimary care physician perceptions on the diagnosis and management of chronic obstructive pulmonary disease in diverse regions of the worldInt J Chron Obstruct Pulmon Dis2012727128222563246
   PubMed Web of Science ®Google Scholar
• KelkelEHerengtFBen SaidaneHCOLIBRI: Improving clinical practice and producing relevant scientific dataRev Mal Respir201633151626163395
   PubMed Web of Science ®Google Scholar
• BuhlRCriéeCPKardosPA year in the life of German patients with COPD: the DACCORD observational studyInt J Chron Obstruct Pulmon Dis2016111639164627499620
   PubMed Web of Science ®Google Scholar
• VogelmeierCWorthHBuhlR“Real-life” inhaled corticosteroid withdrawal in COPD: a subgroup analysis of DACCORDInt J Chron Obstruct Pulmon Dis20171248749428203072
   PubMed Web of Science ®Google Scholar
• ValentiniFDevouassouxGBelhassenMCaractéristiques des patients BPCO initiant un traitement de fond en France: une analyse EGB [Characteristics of COPD patients initiating a long-term therapy in France: an EGB analysis]. Congrès de Pneumologie de Langue Française (CPLF)Rev Mal Respir201835SupplA10 French
   Google Scholar
• KurmiOPVaucherJXiaoDValidity of COPD diagnoses reported through nationwide health insurance systems in the People’s Republic of ChinaInt J Chron Obstruct Pulmon Dis20161141943027042034
   PubMed Web of Science ®Google Scholar
• CookeCRJooMJAndersonSMThe validity of using ICD-9 codes and pharmacy records to identify patients with chronic obstructive pulmonary diseaseBMC Health Serv Res2011113721324188
   PubMed Web of Science ®Google Scholar
• ThomsenRWLangePHellquistBValidity and underrecording of diagnosis of COPD in the Danish National Patient RegistryRespir Med201110571063106821320769
   PubMed Web of Science ®Google Scholar